2020
DOI: 10.26442/18151434.2020.2.200153
|View full text |Cite
|
Sign up to set email alerts
|

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma

Abstract: This article reviews clinical case of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer and the usage of osimertinib for its treatment. Targeted drugs, EGFR tyrosine kinase inhibitors were approved for the treatment of non-small cell lung cancer more than 15 years ago*. Updated results of the large multicenter randomized FLAURA trial showed that osimertinib, a third-generation irreversible selective epidermal growth factor receptor tyrosine kinase inhibitor, was more effectiv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 21 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?